Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Core Viewpoint - Fractyl Health, Inc. has announced a pricing of an underwritten offering of 60 million shares of common stock at $1.00 per share, aiming to raise approximately $60 million in gross proceeds before expenses [1][8]. Company Overview - Fractyl Health is a metabolic therapeutics company focused on innovative treatments for metabolic diseases, particularly obesity and type 2 diabetes (T2D) [5][12]. - The company aims to shift the treatment paradigm from chronic symptomatic management to durable disease-modifying therapies that address the root causes of metabolic diseases [5][12]. - Fractyl has a strong intellectual property portfolio, including 33 granted U.S. patents and around 40 pending U.S. applications, along with numerous foreign patents [5][12]. Offering Details - The underwritten offering is expected to close on or about September 29, 2025, subject to customary closing conditions [1][8]. - BofA Securities and Evercore ISI are serving as joint book-running managers, while Ladenburg Thalmann is the lead manager for the offering [2][9]. - A shelf registration statement for the offering was filed with the SEC on March 3, 2025, and was declared effective on March 18, 2025 [3][10].